|
|
|
Iteos Therapeutics Inc (NASDAQ: ITOS) |
|
|
|
| |
Iteos Therapeutics Inc Outlook |
On March 5 2025 the Iteos Therapeutics Inc provided following guidance
### iTeos Therapeutics Inc. Financial and Business Overview – March 5, 2025
iTeos Therapeutics Inc. has released its financial results for the fourth quarter and the entire fiscal year of 2024, accompanied by several important business updates. The company is strategically positioned with a robust financial foundation, boasting a cash and investment balance of $655.0 million as of December 31, 2024. This substantial financial reserve is projected to sustain the company's operational needs well into 2027.
#### Key Business Updates:
- nnClinical Trials Progressnn: iTeos anticipates the release of a significant interim dataset from its GALAXIES Lung-201 study, which involves over 240 patients. This data is expected to be available in the second quarter of 2025.
- nnFurther Developments in Ongoing Trialsnn: Additionally, interim datasets from the GALAXIES HandN-202 study and the TIG-006 trial for head and neck squamous cell carcinoma (HNSCC) are expected in 2025, with around 200 patients participating in these studies.
- nnPhase 1 Trial Milestonesnn: The company has successfully completed the enrollment of the second dose cohort for its ongoing Phase 1 trial of the EOS-984 molecule in combination with pembrolizumab.
- nnUpcoming Patient Enrollmentnn: The enrollment for the TRM-010 Phase 1 trial involving EOS-215 is anticipated to commence in the second quarter of 2025.
In summary, iTeos Therapeutics is on a solid trajectory, underscored by considerable financial resources and promising developments in its clinical pipeline. The expected timelines for interim data from key studies will be critical metrics for investors and stakeholders to monitor in the coming months.,
|
On May 10 2024 the Iteos Therapeutics Inc provided following guidance
iTeos Therapeutics Inc. reported their financial results for the first quarter of 2024 and shared several important updates regarding their business operations.
One significant development is that the combination of belrestotug and dostarlimab has shown promising results in the Phase 2 GALAXIES Lung-201 trial, surpassing the pre-defined efficacy criteria. This combination therapy demonstrated clinically relevant activity compared to monotherapy, with notable tumor reduction observed across all dosage levels.
Furthermore, iTeos has announced that GSK will provide a comprehensive update on the GALAXIES program at an investor event scheduled for June. This update will likely shed light on the progress and future prospects of the program.
In terms of financial news, RA Capital and Boxer Capital have led a $120 million registered direct offering at $17.50 per share, representing a substantial premium of approximately 44% to the previous closing price. This offering adds to the company's robust financial position, with a pro forma cash and investment balance of $715 million as of March 31, 2024. This strong financial foundation is expected to support iTeos through 2027 as they continue to meet key milestones across their portfolio.
Overall, these developments demonstrate iTeos Therapeutics' commitment to advancing innovative therapies and achieving meaningful progress in the field of oncology.
|
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.
